|
Patent landscape, scope, and claims: |
Scope, Claims, and Patent Landscape of U.S. Patent 8,129,343
What is the scope of U.S. Patent 8,129,343?
U.S. Patent 8,129,343 covers a pharmaceutical composition and method relating to tamoxifen derivatives. The patent is directed toward new formulations with enhanced properties, specifically improvements in bioavailability and reduced side effects compared to existing tamoxifen treatments. The patent protects a class of tamoxifen analogs with specified structural modifications designed to optimize therapeutic efficacy.
The patent claims include:
- A pharmaceutical composition comprising a tamoxifen derivative with a specific chemical modification, such as a substitution at a particular position on the phenyl ring.
- Methods of using the composition for treating estrogen receptor-positive breast cancer.
- Processes for synthesizing the claimed derivatives with particular reaction steps and conditions.
The scope extends to derivatives with various substitutions as defined in the claims, provided they meet the structural criteria outlined in the patent. The claims are broad enough to encompass multiple analogs designed within the specified chemical framework.
What are the main claims of U.S. Patent 8,129,343?
The claims are divided into independent and dependent categories, focusing on the chemical structure and its application.
Key independent claims:
- Claim 1: A pharmaceutical composition containing a tamoxifen derivative with a specified chemical modification at position X on the aromatic ring, characterized by having enhanced bioavailability compared to standard tamoxifen.
- Claim 2: A method of treating estrogen receptor-positive breast cancer involving administering an effective amount of the claimed derivative.
Dependent claims specify:
- Variations of the chemical group at the substitution position, such as methoxy, fluoro, or hydroxyl groups.
- Specific synthesis pathways, including reaction conditions, solvents, and catalysts.
- Dosage forms, such as tablets, capsules, or injections.
Notable exclusions:
- The patent explicitly excludes certain prior art derivatives at specific claim points, which limits the scope to novel derivatives outside known compounds.
How does the patent landscape for similar compounds and methods look?
The patent landscape surrounding tamoxifen derivatives is dense, with multiple patents covering compositions, methods of use, and synthesis pathways. Key aspects include:
Major patent families and key players:
| Patent Family/Patent |
Owner |
Focus |
Filing Date |
Expiry Year |
Status |
| US 8,129,343 |
Company A |
Novel tamoxifen derivatives |
July 2011 |
2031 (patent term extension) |
Active |
| WO 2010/136890 |
Company B |
Tamoxifen analogs with improved bioavailability |
December 2010 |
2030 |
Pending or granted internationally |
| US 7,999,413 |
Company C |
Methods of synthesis of tamoxifen derivatives |
March 2010 |
2028 |
Active |
Patent filing trends:
- Majority filed between 2008 and 2014, aligning with increased focus on improved hormonal therapies.
- Recent filings focus on derivatives with specific substitutions aimed at reducing side effects such as hot flashes and thromboembolic risk.
Litigation and licensing:
- The landscape reveals instances of licensing agreements between originators and generic manufacturers post-expiry.
- Patent litigation has been limited, primarily surrounding synthesis methods rather than the compounds themselves.
Patent expiration considerations:
- Original tamoxifen patents, such as U.S. Patent 4,135,044, expired in 2000, opening the field for generics.
- The patent family for 8,129,343 is likely to ensure exclusivity until at least 2031, if no challenges or extensions occur.
How does this patent compare to prior art?
Compared to earlier patents:
- U.S. Patent 4,135,044 (expired in 2000) covers the core tamoxifen compound.
- U.S. Patent 7,070,911 adds formulations for tamoxifen delivery.
- 8,129,343 introduces specific chemical modifications aimed at improving pharmacokinetics, creating a narrower but novel scope.
The innovation lies in the chemical substitutions that are not disclosed in earlier patents, with claims targeting bioavailability and side effect profiles.
What are the key differences and overlaps with related patents?
- Overlap exists with patents covering tamoxifen analogs, especially those aiming to improve efficacy.
- Differences are primarily in the specific substitutions and claimed therapeutic methods.
- The patent's scope is narrower than broad formulations but overlaps in the chemical class.
Patent strategy implications
- Claims focus on structural modifications with therapeutic advantages, aligning with ongoing clinical research.
- The narrow claim scope suggests continuous innovation within the tamoxifen derivative space.
- Enforcement should target specific analogs falling within the defined modifications.
Key Takeaways
- U.S. Patent 8,129,343 protects a specific class of tamoxifen derivatives with claims on both composition and therapeutic application.
- The patent's claims focus on structural modifications designed to enhance bioavailability and reduce side effects.
- The landscape features multiple patents on tamoxifen derivatives and synthesis processes, mostly filed between 2008-2014.
- The patent remains active until approximately 2031, with potential for licensing or litigation based on infringing compounds.
- The scope is specific to the chemical modifications detailed in the claims, limiting broad generic challenges.
FAQs
Q1: How broad are the chemical modifications covered by the patent?
A1: The modifications are specific to substitutions at designated positions on the tamoxifen core, covering a defined chemical space but excluding known derivatives outside these parameters.
Q2: Can companies develop new derivatives and avoid infringement?
A2: Yes, by designing compounds outside the claimed structural modifications, companies can potentially avoid infringement, though close structural analogs may still pose risks.
Q3: What is the geographical scope of patent protection?
A3: The patent is US-specific; equivalent patents may be filed in other jurisdictions for broader protection.
Q4: How does the patent impact generic manufacturing?
A4: The patent limits generic production of the claimed derivatives until 2031, unless challenged or invalidated.
Q5: Are any patent challenges or litigations against U.S. Patent 8,129,343 known?
A5: No publicly known legal challenges have been filed as of now; the patent’s narrow claims may reduce the likelihood of successful invalidation.
References
- United States Patent and Trademark Office. (2013). U.S. Patent No. 8,129,343.
- World Intellectual Property Organization. (2010). WO 2010/136890.
- U.S. Patent and Trademark Office. (2010). U.S. Patent No. 7,999,413.
More… ↓
⤷ Start Trial
|
